Photocure ASA
OSE:PHO
Intrinsic Value
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. [ Read More ]
The intrinsic value of one PHO stock under the Base Case scenario is 92 NOK. Compared to the current market price of 65.3 NOK, Photocure ASA is Undervalued by 29%.
Valuation Backtest
Photocure ASA
Run backtest to discover the historical profit from buying and selling PHO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Balance Sheet Decomposition
Photocure ASA
Current Assets | 372.4m |
Cash & Short-Term Investments | 259.5m |
Receivables | 75.7m |
Other Current Assets | 37.2m |
Non-Current Assets | 338.8m |
PP&E | 33.5m |
Intangibles | 256.5m |
Other Non-Current Assets | 48.8m |
Current Liabilities | 77.5m |
Accounts Payable | 19.7m |
Other Current Liabilities | 57.9m |
Non-Current Liabilities | 151.6m |
Other Non-Current Liabilities | 151.6m |
Earnings Waterfall
Photocure ASA
Revenue
|
500.7m
NOK
|
Cost of Revenue
|
-26.1m
NOK
|
Gross Profit
|
474.5m
NOK
|
Operating Expenses
|
-446.7m
NOK
|
Operating Income
|
27.8m
NOK
|
Other Expenses
|
-27.5m
NOK
|
Net Income
|
267k
NOK
|
Free Cash Flow Analysis
Photocure ASA
NOK | |
Free Cash Flow | NOK |
PHO Profitability Score
Profitability Due Diligence
Photocure ASA's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Photocure ASA's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
PHO Solvency Score
Solvency Due Diligence
Photocure ASA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Photocure ASA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHO Price Targets Summary
Photocure ASA
According to Wall Street analysts, the average 1-year price target for PHO is 100.98 NOK with a low forecast of 85.85 NOK and a high forecast of 131.25 NOK.
Shareholder Return
PHO Price
Photocure ASA
Average Annual Return | 30.92% |
Standard Deviation of Annual Returns | 49.65% |
Max Drawdown | -73% |
Market Capitalization | 1.8B NOK |
Shares Outstanding | 26 943 800 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
Officers
The intrinsic value of one PHO stock under the Base Case scenario is 92 NOK.
Compared to the current market price of 65.3 NOK, Photocure ASA is Undervalued by 29%.